The paradox of triple negative breast cancer: Novel approaches to treatment Journal Article
| Authors: | Fornier, M.; Fumoleau, P. |
| Article Title: | The paradox of triple negative breast cancer: Novel approaches to treatment |
| Abstract: | Breast cancer that lacks expression of estrogen/progesterone receptors and overexpression of the human epidermal growth factor receptor2 (HER2), i.e. triple-negative breast cancer (TNBC), is not amenable to current targeted therapies and carries a poor prognosis. This review discusses the natural history of TNBC and published literature in the relevant treatment landscape, with a focus on newer therapies. Compared with other subtypes of breast cancer, TN tumors have higher response rates to neoadjuvant chemotherapy; however, this advantage is not clearly translated into the metastatic setting and has not improved these patients' overall survival. Numerous cytotoxic and targeted strategies have demonstrated efficacy or are under investigation. Strategies showing promise in this difficult-to-treat group of patients include cytotoxic therapy with platinum-containing agents, ixabepilone, and novel targeted approaches such as poly(ADP-ribose) polymerase inhibitors. © 2011 Wiley Periodicals, Inc. |
| Keywords: | cancer survival; treatment response; survival rate; unclassified drug; overall survival; clinical feature; drug tolerability; cancer recurrence; bevacizumab; cisplatin; cytotoxic agent; sunitinib; cancer combination chemotherapy; cancer risk; monotherapy; nonhuman; unspecified side effect; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; cancer adjuvant therapy; chemotherapy, adjuvant; neoadjuvant therapy; antineoplastic agent; cancer incidence; dna repair; carboplatin; unindexed drug; metastasis; progression free survival; epidermal growth factor receptor 2; tumor markers, biological; receptor, epidermal growth factor; antineoplastic activity; cytotoxicity; dasatinib; breast neoplasms; brca1 protein; brca2 protein; cetuximab; cancer therapy; distant metastasis; cancer resistance; docetaxel; irinotecan; drug mechanism; systematic review; heat shock protein 90 inhibitor; cancer registry; cancer relapse; platinum; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; taxane derivative; premenopause; trabectedin; mammalian target of rapamycin inhibitor; anthracycline; angiogenesis inhibitors; race difference; drug sensitivity; ixabepilone; epothilones; eribulin; olaparib; randomized controlled trial (topic); molecularly targeted therapy; poly(adp-ribose) polymerases; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); iniparib; triple negative breast cancer; platinum agents; cross-linking reagents; triple-negative breast cancer; entinostat; bosutinib; poly(adp-ribose) polymerase; novel agents; an 162 |
| Journal Title: | Breast Journal |
| Volume: | 18 |
| Issue: | 1 |
| ISSN: | 1075-122X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2012-01-01 |
| Start Page: | 41 |
| End Page: | 51 |
| Language: | English |
| DOI: | 10.1111/j.1524-4741.2011.01175.x |
| PROVIDER: | scopus |
| PUBMED: | 22098334 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 March 2012" - "CODEN: BRJOF" - "Source: Scopus" |
